Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Livzon Pharmaceutical Group ( (HK:1513) ) has issued an announcement.
Livzon Pharmaceutical Group has announced the cancellation of its Supervisory Committee, with its functions now being transferred to the Audit Committee under the Board. This move is part of a broader effort to standardize operations and enhance corporate governance in alignment with updated legal provisions. Additionally, the company has proposed amendments to its Articles of Association and procedural rules for meetings to further improve its governance structure. These changes are expected to streamline operations and ensure compliance with the latest regulatory requirements, potentially impacting the company’s operational efficiency and stakeholder relations.
The most recent analyst rating on (HK:1513) stock is a Buy with a HK$48.00 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group is a company operating in the pharmaceutical industry, focusing on the development and production of medications and healthcare products. The company is known for its commitment to improving healthcare and has a significant presence in the pharmaceutical market.
Average Trading Volume: 1,513,250
Technical Sentiment Signal: Buy
Current Market Cap: HK$34.39B
See more insights into 1513 stock on TipRanks’ Stock Analysis page.